Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer

This study is testing a combination of two cancer drugs — carilizumab (an immunotherapy) and albumin-bound paclitaxel (a chemotherapy) — as a second-line treatment for people with advanced stomach or gastroesophageal junction cancer. **You may be eligible if...** - You are 18–75 years old - You have been diagnosed with stomach or gastroesophageal junction cancer (confirmed by tissue biopsy) - Your cancer got worse after receiving first-line chemotherapy, with or without immunotherapy - You are in generally good health (able to carry out normal activities with some limitations) - Your heart, liver, and kidneys are working well - Your cancer is HER2-negative - You are willing to use reliable contraception during and for 6 months after treatment **You may NOT be eligible if...** - Your cancer has spread to the brain - You had a gastrointestinal perforation or fistula in the past 6 months - You have an active autoimmune disease (like lupus or rheumatoid arthritis) - You have been treated with paclitaxel before - You are pregnant or breastfeeding - You have HIV, active hepatitis B or C, or a history of organ transplant - You have uncontrolled heart problems Talk to your doctor to see if this trial is right for you.